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Abstract
Bacterial infection (BI) is a common cause of impairment 
of liver function in patients with cirrhosis, especially in 
the liver transplant candidates. These patients share an 
immunocompromised state and increased susceptibility 
to develop community and hospital-acquired infections. 
The changing epidemiology of BI, with an increase of 
multidrug resistant strains, especially in healthcare-
associated settings, represents a critical issue both in 
the waiting list and in the post-operative management. 
This review focused on the role played by BI in patients 
awaiting liver transplantation, evaluating the risk of 
drop-out from the waiting list, the possibility to undergo 
liver transplantation after recovery from infection or 
during a controlled infection. 
Key words: Cirrhosis; Portal hypertension; Bacterial 
infection; Liver transplantation
© The Author(s) 2018. Published by Baishideng Publishing 
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Core tip: Bacterial infection (BI) is a common cause of 
impairment of liver function in patients with cirrhosis, 
especially in the liver transplant candidates. BI may play a 
detrimental role in patients awaiting liver transplantation, 
increasing the risk of drop-out from the waiting list. 
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INTRODUCTION
The liver is actively involved in inflammatory response 
against bacteria, and plays a central role in the regulation 
of immune defense, bacterial clearance, acute-phase 
protein, cytokine production and metabolic adaptation 
to inflammation[1]. Conversely, sepsis-induced hypoxic 
hepatitis and cholestasis make hepatic dysfunction 
an independent predictor of mortality during bacterial 
infection (BI)[2,3]. 
Cirrhosis is per se an immunocompromised state 
which predisposes to the development of BI, and sepsis-
related death[4]. It’s characterized by an immunodeficient 
state due to an impaired response to pathogens at 
different levels of the immune system, involving innate 
and adaptive cell dysfunction[5]; this condition coexists with 
a persistent stimulation of immune system, with enhanced 
serum levels of pro-inflammatory cytokines[6,7]. The 
severity of this inflammatory state correlates with severity 
of liver dysfunction[8,9]. Moreover, other superimposed 
conditions - such as impaired gut microbiota and intestinal 
barrier dysfunction - further increase the risk of BI[10]. In a 
study by Rasaratnam et al[11], when patients were treated 
with selective intestinal decontamination, their hepatic 
venous pressure gradient decreased by a mean of 2.43 
mmHg, further strengthening the hypothesis that bacteria 
contribute to the hyperdynamic circulation and portal 
hypertension in cirrhosis. 
Sepsis-related organ damage in cirrhosis is charac-
terized by both an excessive inflammatory response and 
a decrease in the hepatic capacity of tolerance[12]. This 
further increases circulatory dysfunction, with splanchnic 
vasodilation and organ hypo-perfusion[13,14], leading 
to worsening of portal hypertension (via activation of 
neurohumoral pathways) and fluid retention[15]. Develop-
ment of BI is a common trigger of extra-hepatic organ 
failures, in particular acute kidney injury[16], hepatic ence-
phalopathy[17], coagulopathy[18], adrenal insufficiency[19] 
and respiratory failure[20].
CHANGING EPIDEMIOLOGY 
OF BACTERIAL INFECTION IN 
DECOMPENSATED CIRRHOSIS
In the past decades, there have been several improve-
ments in the management of cirrhosis and its compli-
cations, such as hepatocellular carcinoma and portal 
hypertension. However, a significant proportion of 
patients with decompensated cirrhosis still need liver 
transplantation (LT), which represents the only effective 
therapeutic option. 
In this setting, development of BI could significantly 
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impair the natural history of the liver transplant can-
didate[21,22]. Preventive and therapeutic strategies for 
most of the complications of cirrhosis are well-defined; 
nevertheless, even if risk factors for the onset of BI in 
decompensated patients awaiting LT are well-known, 
they remain poor preventable. 
The protean epidemiology of BI in cirrhosis depends 
on several factors, such as site of infection, setting of BI 
development, and local epidemiology.
Spontaneous bacterial peritonitis (SBP) and urinary 
tract infections are the most frequent BI in cirrhosis, 
followed by pneumonia, skin and soft tissue infections, 
bloodstream infections (BSI)[12,23]. SBP is mainly due 
to bacterial translocation - especially gram-negative 
strains[24], however epidemiology is rapidly changing. A 
multicenter study from Portugal[25], evaluating patients 
with severe liver dysfunction (median Child-Pugh class 
C-10; MELD score 19) recently showed an increase in 
gram-positive bacteria (GPB, 42%) at diagnosis of SBP; 
notably, one out of three SBP episodes occurred during 
hospitalization. This has determined the adoption of 
new antibiotic strategies: Piano et al[26] demonstrated 
that the combination of broad-spectrum antibiotics, 
meropenem plus daptomycin, was significantly more 
effective than conventional therapy (ceftazidime) in 
the treatment of nosocomial SBP (86.7% vs 25%; P < 
0.001). 
BSI represent another common cause of BI in 
cirrhosis[12], mainly due to gram-positive strains[27], 
because of the high number of invasive procedures and 
quinolone prophylaxis. However, there’s an increasing 
prevalence of gram-negative bacteria (GNB) as the 
cause of BSI; Bartoletti et al[28] showed in a multicenter 
observational study on 312 cirrhotic patients in Italy, an 
equal distribution between GNB and GPB (53% vs 47%) 
at diagnosis of BSI. 
In the last decades, clinical practice in Hepatology 
has dramatically changed as a consequence of the 
implementation of the liver transplant programs. 
Cirrhotic patients are nowadays frequently admitted to 
the ICU and undergo many diagnostic and therapeutic 
invasive procedures. This is associated with a higher 
risk of secondary infections caused by nonclassical 
pathogens. Fernandez et al[29] included 572 BI, 39% 
of which were nosocomial, reporting an increase in the 
rate of GPB infections associated with the increasing use 
of invasive procedures during hospitalization and in the 
ICU. More recently, Merli et al[30], collected 173 episodes 
of BI requiring hospitalization or occurred during 
hospitalization in 424 patients with cirrhosis; BI episodes 
were further divided into three classes (community 
acquired, hospital acquired, health-care acquired). 
GNB were more frequent in community acquired and 
health-care acquired infections, while GPB in hospital-
acquired ones. Enterobacteriaceae (44.3%) (particularly 
Escherichia coli, Klebsiella pneumoniae and Proteus 
mirabilis) and Enterococci (Enterococcus faecium and 
Enterococcus faecalis) (19.7%), were the pathogens 
most frequently responsible for infection.
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The spreading of multidrug resistant (MDR) bacteria-
related infection is alarming worldwide[31,32]. In the past, 
patients with cirrhosis remained largely unaffected by this 
phenomenon because they were rarely admitted to the 
ICU. Nowadays, frequent hospitalizations, development 
of LT programs and antibiotic prophylaxis made cirrhosis 
at high risk of MDR infections[33]. A multicenter study in 
Italy[34] reported a 27% (83/395) prevalence of MDR 
infections, mainly due to GNB (extended-spectrum 
β lactamase E. Coli and Carbapenems resistant K. 
Pneumoniae). Another study from Greece[35] reported 
19% MDR infection rate amongst patients with SBP, 
being MDR bacteria associated with healthcare-acquired 
infections and with patients at higher MELD score (28 vs 
19, P = 0.012). Also in the above-mentioned study by 
Merli et al[30], MDR infections occurred more frequently 
during hospitalization (56% in hospital acquired/
healthcare-associated infections vs 22% in community 
acquired infections, P = 0.008). 
RISK FACTORS FOR BACTERIAL 
INFECTION IN END STAGE LIVER DISEASE 
Patients with end stage liver disease, listed for LT, have 
the highest risk for BI development. This might be due 
to frequent hospitalizations, severity of liver dysfunction 
and multiorgan failure (Table 1). Correlation between 
the development of BI and severity of liver disease has 
been widely demonstrated[36]. In a Japanese group of 
patients with cirrhosis and hepatocellular carcinoma[37], 
incidence of BI rose from 2.3% in Child-Pugh class A 
patients to 25.6% in Child-Pugh class C patients. In 
a further study[38], even if patients with cirrhosis were 
younger and had less cardiopulmonary comorbidities 
than patients without cirrhosis, they had higher rates of 
septic shock at hospital admission, and equal mortality. 
Moreover, bacteremia and mortality increased with the 
severity of liver disease (5.6%, 20.5%, 33.3% and 
0%, 8.5%, 38.9% in Child-Pugh classes A, B, and C, 
respectively; P = 0.038). 
Furthermore, low serum albumin, ICU admission, 
and GI bleeding, are other independent predictors of BI 
development, according to Deschenes et al[39]. Merli et 
al[40] analyzing 54 BI episodes occurred in 50 patients, 
showed that, at multivariate analysis, a MELD score 
≥ 15 (OR: 2.8, 95%CI: 1.3-6.1), history of previous 
infection within 12 mo (OR: 4.7, 95%CI: 2.2-10.6), 
and a diagnosis of malnutrition (OR: 4; 95%CI: 1.5-10) 
were independent predictors for infections and sepsis. 
Variceal bleeding is another predictor of BI onset; 
Tandon et al[41], reviewing the available literature on 
patients admitted for GI bleeding without receiving 
antibiotic prophylaxis, showed that 242 out of 552 (44%) 
developed an episode of BI. Severity of GI bleeding, 
according to blood transfusion requirements (HR: 1.22; 
95%CI: 1.01-1.47), mean arterial pressure (HR: 0.96; 
95%CI: 0.93-0.99) were independent predictors for 
BI onset[42]. In another Spanish study[29], 126 patients 
underwent at least one invasive procedure, comprising 
variceal sclerotherapy or banding, surgical intervention, 
trans-jugular intrahepatic portosystemic shunt, having a 
higher probability of developing BI due to GPB. 
Sinclair et al[43] showed that 43% of LT candidates 
required at least one hospitalization within 1 year; 
moreover, a significant proportion of hospitalized patients 
(> 45%) required repetitive hospitalisations. Patients 
with cirrhosis have 4 to 5-fold higher probability to 
develop a BI episode during hospitalization than non 
cirrhotic population[42,44].
The role of etiology of underlying liver disease as 
a risk factor for BI development is debated[45]. Alcohol 
abuse is associated with increased intestinal per-
meability, dysbiosis and increased bacterial trans-
location[46]. Furthermore, Legionella and Mycobacterium 
tuberculosis infections are significantly more prevalent 
in patients with alcohol abuse[47,48]. In the setting of 
cirrhosis, several studies reported a higher rate of BI 
in patients with alcoholic etiology when compared 
with non-alcoholic[49,50]. Sargenti et al[51] evaluating 
characteristics of 398 BI in 633 cirrhotics (363 alcoholic, 
270 nonalcoholic), reported a similar occurrence of BI 
between groups, but pointed out that alcohol related 
disease was significantly associated with bacterial 
pneumonia and GPB.
IMPACT OF BACTERIAL INFECTIONS IN 
LIVER FUNCTION
Worsening of liver function is frequently observed 
in patients with infection, especially in those with 
sepsis, being itself a trigger for multiorgan failure, 
and development of Acute on Chronic Liver Failure 
(ACLF)[52-54]. 
In the above-mentioned study by Merli et al[40], 
Child–Pugh and MELD scores worsened in 62% of 
patients after infection; moreover, onset of ascites, 
hepatic encephalopathy, hyponatremia, hepatorenal 
Table 1  Risk factors of bacterial infection in cirrhosis
Risk factors for bacterial infection in cirrhosis
Impairment of liver function 
  Child-Pugh score[36-38]
  MELD score ≥ 15[40]
  Low serum albumin[39]
Alcohol related disease[45,51]
Total ascitic fluid protein concentration < 15 g/L[84]
ICU admission[39,85]
Variceal bleeding[41,86]
  Blood transfusion requirements
  Mean arterial pressure
  Severity of bleeding
Malnutrition[40]
Invasive procedures[29]
ERCP in PSC patients or with incomplete drainage[87]
Hospitalization[29,40,43,44]
MELD: Model for end stage liver disease; ICU: Intensive care unit; 
ERCP: Endoscopic retrograde cholangiopancreatography; PSC: Primary 
sclerosing cholangitis.
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(3 d vs 2 d, P = 0.05), and longer post-transplant 
hospitalization (29 d vs 20 d, P = 0.05). However, 
post-transplant mortality was not different between 
groups (9.4% vs 2.9%) and was not associated with 
pre-LT infection. Lin et al[64] retrospectively analyzed 
the outcome of 34 living donor LT candidates who 
had experienced an episode of BI within 4 wk prior 
surgery, which was effectively treated (e.g., dis-
appearance of symptoms and signs suggestive of 
sepsis, normalization or improvement of laboratory 
and/or imaging findings after antibiotic therapy). 
The post-operative outcome was compared with 20 
patients with pre-LT ACLF without infection. The only 
difference between groups was the longer total hospital 
stay (89.0 d vs 65.5 d, P = 0.024), whereas post-LT 
ICU stay, one-year survival, and post-LT infection rates 
were similar between groups. Few data are available on 
the possibility to offer a standardized MELD exception 
after recovery from infection[65-67]. A possible scenario 
is the onset of recurrent episodes of cholangitis in PSC 
candidates; in a study by Goldberg et al[68], 300 patients 
who received MELD exception points for an increased 
risk of waitlist mortality, had a lower proportion of 
death/drop out (20.0% vs 1.3% P < 0.001); however, 
this non-standardized exception has not been further 
confirmed.
Several studies recently investigated the outcome of 
patients who underwent LT under “controlled” infection. 
In an Italian study[69], 84 patients were considered 
eligible for LT after disappearance of symptoms and 
signs suggestive of severe sepsis/septic shock. The 
overall post-LT 90-d mortality, septic shock, and sepsis 
as cause of death were not significantly different 
between infected and not-infected LT recipients; 
however, patients with previous infection had in the 
post-operative course higher rates of infections (40% 
vs 36%, P = 0.003) and post-transplant MDR strains 
(26% vs 13%, P = 0.005). Artru et al[70] recently 
demonstrated that ACLF grade 3 patients were 
transplanted in France after they had recovered from 
an episode of BI according to a subjective criterion of 
“controlled sepsis” for at least 24 h within transplant; 
the authors demonstrated an excellent 1-year post-LT 
survival (83.8%), not different than that observed in 
patients with no ACLF or with lower stages of ALCF. 
MDR bacteria colonization represents another 
important issue in the setting of WL, because of the risk 
of spreading of BI in the post-operative course and/or 
after the introduction of immunosuppression. Giannella 
et al[71] prospectively evaluate the role of carbapenems 
resistant K. Pneumoniae (CR-KP) colonization (e.g., 
presence of MDR bacteria in the rectal swab in absence 
of symptoms and signs of active infection) in 237 
patients awaiting LT, of whom 11 (4.6%) were positive 
at the time of LT. Hospital admission, higher MELD at LT, 
prior antibiotic exposure, post-operative complications, 
and ICU length of stay were the factors associated 
with the CR-KP active infection after LT. In addition, 
the same group, performing a multicenter prospective 
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syndrome, were more frequent in patients with infection 
as compared with those who were not infected. 
Prognosis of BI significantly correlates with the 
severity of liver disease and with the severity of extra-
hepatic organ involvement[54,55]. A systematic review[21] 
considering 11987 patients with an episode of BI from 
178 different studies, reported 1-, 3-, and 12-mo 
mortality of 30.3%, 44%, and 63%, respectively, and 
almost half of patients surviving at 1 mo died within a 
year. Renal failure, stage of cirrhosis (according to Child-
Pugh score), age and severe sepsis were the factors 
independently associated with death. Several studies 
confirmed the critical role of renal failure in patients 
with cirrhosis and BI[56,57]. Mortality increased with the 
occurrence and severity of acute kidney injury and with 
the outcome of renal failure (15% 90-d mortality after 
complete recovery, 40% after partial renal recovery, and 
80% in patients without renal recovery or progression). 
According to the study by Cazzaniga et al[58], systemic 
inflammation and fulfillment of SIRS criteria, are other 
factors significantly associated with mortality, since in-
hospital mortality of these decompensated patients 
with MELD score > 18 rose from 12% to 43%. Dionigi 
et al[22] retrospectively evaluated prognosis of patients 
who were hospitalized in a tertiary center in the 
United Kingdom; they demonstrated that in-hospital 
mortality rate was higher in those patients who had 
infection at admission and/or developed infection during 
hospitalization (HR: 5.02; 95%CI: 2.75–9.16; P < 
0.001). 
IMPACT OF BACTERIAL INFECTION IN 
THE LIVER TRANSPLANT CANDIDATE
The onset of BI usually determines a further worsening of 
liver function and multiorgan failure, with high probability 
of death or drop-out from the WL[59,60]. Reddy et al[61] 
prospectively evaluated the outcome of 136 patients 
after an episode of BI developed while awaiting LT: 42% 
were delisted or died, 35% underwent transplantation, 
and only 24% achieved transplant-free survival within 6 
mo. As expected, those who remained in the waiting list 
had a lower MELD score compared to those who either 
received a transplant or died/delisted; furthermore, 
those patients who underwent LT after BI recovery 
had a significant higher survival than those without 
LT (95% vs 5%; P < 0.001). At univariate analysis, 
the number of organ failures was the main factor that 
predicted death or delisting, whereas MELD score did 
not differentiate between those who were ultimately 
transplanted vs those who were delisted. Mounzer et 
al[62] showed that, 38% of patients who had experienced 
an episode of SBP before waiting list admission, were 
subsequently removed from the list or died. 
Regarding patients who fully recovered from an 
episode of BI, the study by Sun et al[63] showed that 
recipients with pre-transplant BI (n = 32) within 12 mo 
before LT had a higher MELD score (median 25 vs 22, P 
< 0.05) at transplant, higher time of post-LT intubation 
Ferrarese A et al . BI in liver transplantation
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study on CR-KP carriers[72], not only in the setting of 
LT, demonstrated that the number of additional coloni-
zation sites was an independent risk factor for invasive 
infection. 
In conclusion, BI significantly modify the natural 
history of patients with cirrhosis listed for LT. Severe 
BI in a sick and frail patient can produce a multiorgan 
failure comprising further deterioration of liver function. 
Even if this can increase priority in the WL, this gain in 
priority should be used only after adequate control of 
infection. To date, standardized definition of “controlled 
infection” is lacking. As for other patients with severe 
ACLF in the WL[73,74], prioritization rules in the respect of 
distributive justice, definition of the ideal timing for LT 
and definition of delisting criteria have to be refined in 
the next future. 
MEDICAL PROPHYLAXIS OF BACTERIAL 
INFECTION
Antibiotic prophylaxis in patients with decompensated 
cirrhosis is standard of care in patients with recent 
gastrointestinal bleeding[75], and in those with high 
risk of SBP(e.g., Child-Pugh > 9, serum bilirubin > 3 
mg/dL and impaired renal function), or in secondary 
prophylaxis for SBP[24].
Antibiotic prophylaxis after upper GI bleeding reduces 
the incidence of in-hospital infections, re-bleeding rate 
within 7 d (7% vs 34%), and 28-d mortality (13% vs 
35%, P = 0.04). 
However, some concerns about long-term prophylaxis 
has been recently raised, since it’s been associated with 
high prevalence of MDR BI, before and after LT. Tandon 
et al[76] evaluating 110 episodes of BI (30% hospital 
acquired), reported 47% of antibiotic resistance and a 
significant association between previous exposure to 
systemic antibiotics and antibiotic-resistance. Infections 
due to MDR bacteria are associated with an increased 
risk of septic shock, acute kidney injury, and death, in 
the post-transplant setting[44]. Furthermore, antibiotic 
use has been identified as the strongest predictor of 
invasive post-transplant fungal infection, associated with 
a 60% mortality[77]. 
Even if several studies suggested the need to stratify 
patients who need antibiotic prophylaxis, both after 
variceal bleeding and after an episode of SBP, no robust 
data are available to date[12,23,78,79]. 
Patients with cirrhosis admitted to ICU could be at 
higher risk of BI. Recently, a metanalysis on prognosis 
of cirrhotics admitted to ICU showed that acute kidney 
injury and sepsis as indications to ICU admission were 
the only factors significantly associated with mortality[80]. 
Another retrospective study[81] on 42 patients who 
underwent LT from the ICU, showed that pre-LT 
intubation was a factor significantly associated with post-
LT pneumonia (P = 0.02). 
On the contrary, patients who recover liver function 
while in the WL (e.g., after viral eradication/suppres-
sion), history of BI would not be a sufficient factor 
for administering long-term antibiotic prophylaxis. In 
addition, the spreading of MDR bacteria will reduce 
the potential role of antibiotic mono-prophylaxis with 
quinolones or cephalosporines. 
Given the crucial role played by dysbiosis in BI in 
patients with cirrhosis, several studies assessed the role 
of intestinal decontamination. Grat et al[82] evaluated 
the fecal microflora in 40 LT candidates, showing that 
abundance of several species (e.g., Bifidobacterium 
and Enterococcus) significantly correlated with the 
severity of liver disease. In systematic review and 
metanalysis, Safdar et al[83] compared parenteral (e.g., 
cephalosporins/quinolones), topically applied or non-
absorbable antibiotic strategies (polymyxin, gentamicin, 
and nystatin) for intestinal decontamination. The Authors 
found an association between selective decontamination 
and reduction of GNB infections (P = 0.001), however 
studies were underpowered and heterogeneous. 
CONCLUSION
BI represent a turning point in the natural history of 
cirrhosis, being the first cause of development of ACLF, 
and significantly affecting the outcome of patients listed 
for LT. These patients are at the highest risk of infection, 
because of frequent hospitalizations and contacts 
with healthcare facilities, immune dysregulation, end-
stage liver disease. SBP, pneumonia and bloodstream 
infection represent the commonest sites of BI. In such 
cases, early institution of empirical antibiotic therapy 
is mandatory, to reduce infection-related mortality. 
However, empirical antibiotic therapy should take into 
account the changing epidemiology of infections, related 
both to an increase of gram positive strains and to MDR 
bacteria. 
In the setting of LT, patients should be considered 
suitable for transplant after resolution of infection. 
However, according to recent studies, selected patients 
with “controlled infection” should be considered for 
transplant, since this condition does not impair the post-
transplant outcome[69,70]. Antibiotic prophylaxis is the 
standard of care in cirrhotic patients with gastrointestinal 
bleeding or with previous episodes of SBP. However, it 
should be considered also in other settings with a high 
prevalence of BI, as in patients listed for LT, admitted to 
ICU and requiring intubation, because of a higher risk of 
post-LT pneumonia. 
REFERENCES
1 Strnad P, Tacke F, Koch A, Trautwein C. Liver - guardian, 
modifier and target of sepsis. Nat Rev Gastroenterol Hepatol 2017; 
14: 55-66 [PMID: 27924081 DOI: 10.1038/nrgastro.2016.168]
2 Koch A, Horn A, Dückers H, Yagmur E, Sanson E, Bruensing 
J, Buendgens L, Voigt S, Trautwein C, Tacke F. Increased liver 
stiffness denotes hepatic dysfunction and mortality risk in critically 
ill non-cirrhotic patients at a medical ICU. Crit Care 2011; 15: 
R266 [PMID: 22082207 DOI: 10.1186/cc10543]
Ferrarese A et al . BI in liver transplantation
227 February 27, 2018|Volume 10|Issue 2|WJH|www.wjgnet.com
3 Dizier S, Forel JM, Ayzac L, Richard JC, Hraiech S, Lehingue S, 
Loundou A, Roch A, Guerin C, Papazian L; ACURASYS study 
investigators; PROSEVA Study Group. Early Hepatic Dysfunction 
Is Associated with a Worse Outcome in Patients Presenting with 
Acute Respiratory Distress Syndrome: A Post-Hoc Analysis of 
the ACURASYS and PROSEVA Studies. PLoS One 2015; 10: 
e0144278 [PMID: 26636318 DOI: 10.1371/journal.pone.0144278]
4 Foreman MG, Mannino DM, Moss M. Cirrhosis as a risk factor 
for sepsis and death: analysis of the National Hospital Discharge 
Survey. Chest 2003; 124: 1016-1020 [PMID: 12970032 DOI: 
10.1378/chest.124.3.1016]
5 Albillos A, Lario M, Álvarez-Mon M. Cirrhosis-associated 
immune dysfunction: distinctive features and clinical relevance. J 
Hepatol 2014; 61: 1385-1396 [PMID: 25135860 DOI: 10.1016/
j.jhep.2014.08.010]
6 Tazi KA, Quioc JJ, Saada V, Bezeaud A, Lebrec D, Moreau R. 
Upregulation of TNF-alpha production signaling pathways in 
monocytes from patients with advanced cirrhosis: possible role of 
Akt and IRAK-M. J Hepatol 2006; 45: 280-289 [PMID: 16635535 
DOI: 10.1016/j.jhep.2006.02.013]
7 Úbeda M, Muñoz L, Borrero MJ, Díaz D, Francés R, Monserrat 
J, Lario M, Lledó L, Such J, Álvarez-Mon M, Albillos A. Critical 
role of the liver in the induction of systemic inflammation in rats 
with preascitic cirrhosis. Hepatology 2010; 52: 2086-2095 [PMID: 
21105108 DOI: 10.1002/hep.23961]
8 Lee FY, Lu RH, Tsai YT, Lin HC, Hou MC, Li CP, Liao TM, Lin 
LF, Wang SS, Lee SD. Plasma interleukin-6 levels in patients with 
cirrhosis. Relationship to endotoxemia, tumor necrosis factor-
alpha, and hyperdynamic circulation. Scand J Gastroenterol 1996; 
31: 500-505 [PMID: 8734349 DOI: 10.3109/00365529609006772]
9 Tilg H, Wilmer A, Vogel W, Herold M, Nölchen B, Judmaier 
G, Huber C. Serum levels of cytokines in chronic liver diseases. 
Gastroenterology 1992; 103: 264-274 [PMID: 1612333]
10 Wiest R, Lawson M, Geuking M. Pathological bacterial 
translocation in liver cirrhosis. J Hepatol 2014; 60: 197-209 [PMID: 
23993913 DOI: 10.1016/j.jhep.2013.07.044]
11 Rasaratnam B, Kaye D, Jennings G, Dudley F, Chin-Dusting 
J. The effect of selective intestinal decontamination on the 
hyperdynamic circulatory state in cirrhosis. A randomized trial. 
Ann Intern Med 2003; 139: 186-193 [PMID: 12899586 DOI: 
10.7326/0003-4819-139-3-200308050-00008]
12 Jalan R, Fernandez J, Wiest R, Schnabl B, Moreau R, Angeli 
P, Stadlbauer V, Gustot T, Bernardi M, Canton R, Albillos A, 
Lammert F, Wilmer A, Mookerjee R, Vila J, Garcia-Martinez R, 
Wendon J, Such J, Cordoba J, Sanyal A, Garcia-Tsao G, Arroyo 
V, Burroughs A, Ginès P. Bacterial infections in cirrhosis: a 
position statement based on the EASL Special Conference 2013. 
J Hepatol 2014; 60: 1310-1324 [PMID: 24530646 DOI: 10.1016/
j.jhep.2014.01.024]
13 Moreau R, Soubrane O, Sogni P, Hadengue A, Gaudin C, Lin HC, 
Pussard E, Nahoul K, Lebrec D. Hemodynamic, neurohumoral, 
and metabolic responses to amino acid infusion in patients with 
cirrhosis. Gastroenterology 1992; 103: 601-608 [PMID: 1386049]
14 Moreau R, Hadengue A, Soupison T, Kirstetter P, Mamzer MF, 
Vanjak D, Vauquelin P, Assous M, Sicot C. Septic shock in patients 
with cirrhosis: hemodynamic and metabolic characteristics and 
intensive care unit outcome. Crit Care Med 1992; 20: 746-750 
[PMID: 1597026 DOI: 10.1097/00003246-199206000-00008]
15 Thalheimer U, Triantos CK, Samonakis DN, Patch D, Burroughs 
AK. Infection, coagulation, and variceal bleeding in cirrhosis. 
Gut 2005; 54: 556-563 [PMID: 15753544 DOI: 10.1136/
gut.2004.048181]
16 Sort P, Navasa M, Arroyo V, Aldeguer X, Planas R, Ruiz-del-
Arbol L, Castells L, Vargas V, Soriano G, Guevara M, Ginès P, 
Rodés J. Effect of intravenous albumin on renal impairment and 
mortality in patients with cirrhosis and spontaneous bacterial 
peritonitis. N Engl J Med 1999; 341: 403-409 [PMID: 10432325 
DOI: 10.1056/NEJM199908053410603]
17 Merli M, Lucidi C, Pentassuglio I, Giannelli V, Giusto M, Di 
Gregorio V, Pasquale C, Nardelli S, Lattanzi B, Venditti M, Riggio 
O. Increased risk of cognitive impairment in cirrhotic patients 
with bacterial infections. J Hepatol 2013; 59: 243-250 [PMID: 
23523580 DOI: 10.1016/j.jhep.2013.03.012]
18 Plessier A, Denninger MH, Consigny Y, Pessione F, Francoz C, 
Durand F, Francque S, Bezeaud A, Chauvelot-Moachon L, Lebrec 
D, Valla DC, Moreau R. Coagulation disorders in patients with 
cirrhosis and severe sepsis. Liver Int 2003; 23: 440-448 [PMID: 
15002397 DOI: 10.1111/j.1478-3231.2003.00870.x]
19 Fede G, Spadaro L, Tomaselli T, Privitera G, Germani G, 
Tsochatzis E, Thomas M, Bouloux PM, Burroughs AK, Purrello F. 
Adrenocortical dysfunction in liver disease: a systematic review. 
Hepatology 2012; 55: 1282-1291 [PMID: 22234976 DOI: 10.1002/
hep.25573]
20 Doyle RL, Szaflarski N, Modin GW, Wiener-Kronish JP, Matthay 
MA. Identification of patients with acute lung injury. Predictors 
of mortality. Am J Respir Crit Care Med 1995; 152: 1818-1824 
[PMID: 8520742 DOI: 10.1164/ajrccm.152.6.8520742]
21 Arvaniti V, D’Amico G, Fede G, Manousou P, Tsochatzis E, 
Pleguezuelo M, Burroughs AK. Infections in patients with cirrhosis 
increase mortality four-fold and should be used in determining 
prognosis. Gastroenterology 2010; 139: 1246-1256, 1256.e1-5 
[PMID: 20558165 DOI: 10.1053/j.gastro.2010.06.019]
22 Dionigi E, Garcovich M, Borzio M, Leandro G, Majumdar A, 
Tsami A, Arvaniti V, Roccarina D, Pinzani M, Burroughs AK, 
O’Beirne J, Tsochatzis EA. Bacterial Infections Change Natural 
History of Cirrhosis Irrespective of Liver Disease Severity. Am 
J Gastroenterol 2017; 112: 588-596 [PMID: 28220780 DOI: 
10.1038/ajg.2017.19]
23 Fagiuoli S, Colli A, Bruno R, Craxì A, Gaeta GB, Grossi P, 
Mondelli MU, Puoti M, Sagnelli E, Stefani S, Toniutto P, Burra P; 
2011 AISF Single Topic Group. Management of infections pre- and 
post-liver transplantation: report of an AISF consensus conference. 
J Hepatol 2014; 60: 1075-1089 [PMID: 24384327 DOI: 10.1016/
j.jhep.2013.12.021]
24 European Association for the Study of the Liver. EASL clinical 
practice guidelines on the management of ascites, spontaneous 
bacterial peritonitis, and hepatorenal syndrome in cirrhosis. J 
Hepatol 2010; 53: 397-417 [PMID: 20633946 DOI: 10.1016/
j.jhep.2010.05.004]
25 Oliveira AM, Branco JC, Barosa R, Rodrigues JA, Ramos L, 
Martins A, Karvellas CJ, Cardoso FS. Clinical and microbiological 
characteristics associated with mortality in spontaneous bacterial 
peritonitis: a multicenter cohort study. Eur J Gastroenterol 
Hepatol 2016; 28: 1216-1222 [PMID: 27391170 DOI: 10.1097/
MEG.0000000000000700]
26 Piano S, Fasolato S, Salinas F, Romano A, Tonon M, Morando 
F, Cavallin M, Gola E, Sticca A, Loregian A, Palù G, Zanus G, 
Senzolo M, Burra P, Cillo U, Angeli P. The empirical antibiotic 
treatment of nosocomial spontaneous bacterial peritonitis: Results 
of a randomized, controlled clinical trial. Hepatology 2016; 63: 
1299-1309 [PMID: 26084406 DOI: 10.1002/hep.27941]
27 Campillo B, Richardet JP, Kheo T, Dupeyron C. Nosocomial 
spontaneous bacterial peritonitis and bacteremia in cirrhotic 
patients: impact of isolate type on prognosis and characteristics of 
infection. Clin Infect Dis 2002; 35: 1-10 [PMID: 12060868 DOI: 
10.1086/340617]
28 Bartoletti M, Giannella M, Lewis R, Caraceni P, Tedeschi S, 
Paul M, Schramm C, Bruns T, Merli M, Cobos-Trigueros N, 
Seminari E, Retamar P, Mu-oz P, Tumbarello M, Burra P, Torrani 
Cerenzia M, Barsic B, Calbo E, Maraolo AE, Petrosillo N, Galan-
Ladero MA, D’Offizi G, Bar Sinai N, Rodríguez-Ba-o J, Verucchi 
G, Bernardi M, Viale P; ESGBIS/BICHROME Study Group. A 
prospective multicentre study of the epidemiology and outcomes 
of bloodstream infection in cirrhotic patients. Clin Microbiol 
Infect 2017; pii: S1198-743X(17)30426-3 [PMID: 28818628 DOI: 
10.1016/j.cmi.2017.08.001]
29 Fernández J, Navasa M, Gómez J, Colmenero J, Vila J, Arroyo 
V, Rodés J. Bacterial infections in cirrhosis: epidemiological 
changes with invasive procedures and norfloxacin prophylaxis. 
Hepatology 2002; 35: 140-148 [PMID: 11786970 DOI: 10.1053/
Ferrarese A et al . BI in liver transplantation
228 February 27, 2018|Volume 10|Issue 2|WJH|www.wjgnet.com
jhep.2002.30082]
30 Merli M, Lucidi C, Di Gregorio V, Falcone M, Giannelli V, 
Lattanzi B, Giusto M, Ceccarelli G, Farcomeni A, Riggio O, 
Venditti M. The spread of multi drug resistant infections is leading 
to an increase in the empirical antibiotic treatment failure in 
cirrhosis: a prospective survey. PLoS One 2015; 10: e0127448 
[PMID: 25996499 DOI: 10.1371/journal.pone.0127448]
31 Boyle DP, Zembower TR. Epidemiology and Management of 
Emerging Drug-Resistant Gram-Negative Bacteria: Extended-
Spectrum β-Lactamases and Beyond. Urol Clin North Am 2015; 
42: 493-505 [PMID: 26475946 DOI: 10.1016/j.ucl.2015.05.005]
32 Dheda K, Gumbo T, Maartens G, Dooley KE, McNerney R, 
Murray M, Furin J, Nardell EA, London L, Lessem E, Theron 
G, van Helden P, Niemann S, Merker M, Dowdy D, Van Rie A, 
Siu GK, Pasipanodya JG, Rodrigues C, Clark TG, Sirgel FA, 
Esmail A, Lin HH, Atre SR, Schaaf HS, Chang KC, Lange C, 
Nahid P, Udwadia ZF, Horsburgh CR Jr, Churchyard GJ, Menzies 
D, Hesseling AC, Nuermberger E, McIlleron H, Fennelly KP, 
Goemaere E, Jaramillo E, Low M, Jara CM, Padayatchi N, Warren 
RM. The epidemiology, pathogenesis, transmission, diagnosis, 
and management of multidrug-resistant, extensively drug-
resistant, and incurable tuberculosis. Lancet Respir Med 2017; 
pii: S2213-2600(17)30079-6 [PMID: 28344011 DOI: 10.1016/
S2213-2600(17)30079-6]
33 Fernández J, Bert F, Nicolas-Chanoine MH. The challenges 
of multi-drug-resistance in hepatology. J Hepatol 2016; 65: 
1043-1054 [PMID: 27544545 DOI: 10.1016/j.jhep.2016.08.006]
34 Salerno F, Borzio M, Pedicino C, Simonetti R, Rossini A, Boccia 
S, Cacciola I, Burroughs AK, Manini MA, La Mura V, Angeli 
P, Bernardi M, Dalla Gasperina D, Dionigi E, Dibenedetto C, 
Arghittu M; AISF Investigators. The impact of infection by 
multidrug-resistant agents in patients with cirrhosis. A multicenter 
prospective study. Liver Int 2017; 37: 71-79 [PMID: 27364035 
DOI: 10.1111/liv.13195]
35 Alexopoulou A, Papadopoulos N, Eliopoulos DG, Alexaki A, 
Tsiriga A, Toutouza M, Pectasides D. Increasing frequency of 
gram-positive cocci and gram-negative multidrug-resistant bacteria 
in spontaneous bacterial peritonitis. Liver Int 2013; 33: 975-981 
[PMID: 23522099 DOI: 10.1111/liv.12152]
36 Caly WR, Strauss E. A prospective study of bacterial infections 
in patients with cirrhosis. J Hepatol 1993; 18: 353-358 [DOI: 
10.1016/S0168-8278(05)80280-6]
37 Yoshida H, Hamada T, Inuzuka S, Ueno T, Sata M, Tanikawa K. 
Bacterial infection in cirrhosis, with and without hepatocellular 
carcinoma. Am J Gastroenterol 1993; 88: 2067-2071 [PMID: 
8249975]
38 Viasus D, Garcia-Vidal C, Castellote J, Adamuz J, Verdaguer 
R, Dorca J, Manresa F, Gudiol F, Carratalà J. Community-
acquired pneumonia in patients with liver cirrhosis: clinical 
features, outcomes, and usefulness of severity scores. Medicine 
(Baltimore) 2011; 90: 110-118 [PMID: 21358441 DOI: 10.1097/
MD.0b013e318210504c]
39 Deschênes M, Villeneuve JP. Risk factors for the development 
of bacterial infections in hospitalized patients with cirrhosis. Am 
J Gastroenterol 1999; 94: 2193-2197 [PMID: 10445549 DOI: 
10.1111/j.1572-0241.1999.01293.x]
40 Merli M, Lucidi C, Giannelli V, Giusto M, Riggio O, Falcone 
M, Ridola L, Attili AF, Venditti M. Cirrhotic patients are at risk 
for health care-associated bacterial infections. Clin Gastroenterol 
Hepatol 2010; 8: 979-985 [PMID: 20621200 DOI: 10.1016/
j.cgh.2010.06.024]
41 Tandon P, Garcia-Tsao G. Bacterial infections, sepsis, and 
multiorgan failure in cirrhosis. Semin Liver Dis 2008; 28: 26-42 
[PMID: 18293275 DOI: 10.1055/s-2008-1040319]
42 Fernández J, Ruiz del Arbol L, Gómez C, Durandez R, Serradilla 
R, Guarner C, Planas R, Arroyo V, Navasa M. Norfloxacin vs 
ceftriaxone in the prophylaxis of infections in patients with 
advanced cirrhosis and hemorrhage. Gastroenterology 2006; 
131: 1049-1056; quiz 1285 [PMID: 17030175 DOI: 10.1053/
j.gastro.2006.07.010]
43 Sinclair M ,  Poltavskiy E, Dodge JL, Lai JC. Frailty is 
independently associated with increased hospitalisation days in 
patients on the liver transplant waitlist. World J Gastroenterol 
2017; 23: 899-905 [PMID: 28223735 DOI: 10.3748/wjg.v23.
i5.899]
44 Fernandez J, Gustot T. Management of bacterial infections in 
cirrhosis. J Hepatol 2012; 56 Suppl 1: S1-S12 [DOI: 10.1016/
S0168-8278(12)60002-6]
45 Gustot T, Fernandez J, Szabo G, Albillos A, Louvet A, Jalan R, 
Moreau R, Moreno C. Sepsis in alcohol-related liver disease. J 
Hepatol 2017; 67: 1031-1050 [PMID: 28647569 DOI: 10.1016/
j.jhep.2017.06.013]
46 Cirera I, Bauer TM, Navasa M, Vila J, Grande L, Taurá P, 
Fuster J, García-Valdecasas JC, Lacy A, Suárez MJ, Rimola A, 
Rodés J. Bacterial translocation of enteric organisms in patients 
with cirrhosis. J Hepatol 2001; 34: 32-37 [DOI: 10.1016/
S0168-8278(00)00013-1]
47 Happel KI, Nelson S. Alcohol, immunosuppression, and the lung. 
Proc Am Thorac Soc 2005; 2: 428-432 [PMID: 16322595 DOI: 
10.1513/pats.200507-065JS]
48 Lönnroth K, Williams BG, Stadlin S, Jaramillo E, Dye C. 
Alcohol use as a risk factor for tuberculosis - a systematic review. 
BMC Public Health 2008; 8: 289 [PMID: 18702821 DOI: 
10.1186/1471-2458-8-289]
49 Conejo I, Augustin S, Pons M, Ventura-Cots M, González A, 
Esteban R, Genescà J. Alcohol consumption and risk of infection 
after a variceal bleeding in low-risk patients. Liver Int 2016; 36: 
994-1001 [PMID: 26643867 DOI: 10.1111/liv.13038]
50 Rosa H, Silvério AO, Perini RF, Arruda CB. Bacterial infection 
in cirrhotic patients and its relationship with alcohol. Am J 
Gastroenterol 2000; 95: 1290-1293 [PMID: 10811341 DOI: 
10.1111/j.1572-0241.2000.02026.x]
51 Sargenti K, Prytz H, Nilsson E, Bertilsson S, Kalaitzakis E. 
Bacterial infections in alcoholic and nonalcoholic liver cirrhosis. 
Eur J Gastroenterol Hepatol 2015; 27: 1080-1086 [PMID: 
26011234 DOI: 10.1097/MEG.0000000000000396]
52 Mücke MM, Rumyantseva T, Mücke VT, Schwarzkopf K, Joshi S, 
Kempf VAJ, Welsch C, Zeuzem S, Lange CM. Bacterial infection-
triggered acute-on-chronic liver failure is associated with increased 
mortality. Liver Int 2017; Epub ahead of print [PMID: 28853199 
DOI: 10.1111/liv.13568]
53 Sargenti K, Prytz H, Nilsson E, Kalaitzakis E. Predictors of 
mortality among patients with compensated and decompensated 
liver cirrhosis: the role of bacterial infections and infection-related 
acute-on-chronic liver failure. Scand J Gastroenterol 2015; 50: 
875-883 [PMID: 25697824 DOI: 10.3109/00365521.2015.101783
4]
54 Moreau R, Jalan R, Gines P, Pavesi M, Angeli P, Cordoba J, 
Durand F, Gustot T, Saliba F, Domenicali M, Gerbes A, Wendon 
J, Alessandria C, Laleman W, Zeuzem S, Trebicka J, Bernardi M, 
Arroyo V; CANONIC Study Investigators of the EASL–CLIF 
Consortium. Acute-on-chronic liver failure is a distinct syndrome 
that develops in patients with acute decompensation of cirrhosis. 
Gastroenterology 2013; 144: 1426-1437, 1437.e1-1437.e9 [PMID: 
23474284 DOI: 10.1053/j.gastro.2013.02.042]
55 Bruns T, Zimmermann HW, Stallmach A. Risk factors and 
outcome of bacterial infections in cirrhosis. World J Gastroenterol 
2014; 20: 2542-2554 [PMID: 24627590 DOI: 10.3748/wjg.v20.
i10.2542]
56 Martín-Llahí M, Guevara M, Torre A, Fagundes C, Restuccia T, 
Gilabert R, Solá E, Pereira G, Marinelli M, Pavesi M, Fernández J, 
Rodés J, Arroyo V, Ginès P. Prognostic importance of the cause of 
renal failure in patients with cirrhosis. Gastroenterology 2011; 140: 
488-496.e4 [PMID: 20682324 DOI: 10.1053/j.gastro.2010.07.043]
57 Wong F, O’Leary JG, Reddy KR, Patton H, Kamath PS, Fallon 
MB, Garcia-Tsao G, Subramanian RM, Malik R, Maliakkal B, 
Thacker LR, Bajaj JS; North American Consortium for Study 
of End-Stage Liver Disease. New consensus definition of acute 
kidney injury accurately predicts 30-day mortality in patients with 
cirrhosis and infection. Gastroenterology 2013; 145: 1280-1288.e1 
Ferrarese A et al . BI in liver transplantation
229 February 27, 2018|Volume 10|Issue 2|WJH|www.wjgnet.com
[PMID: 23999172 DOI: 10.1053/j.gastro.2013.08.051]
58 Cazzaniga M, Dionigi E, Gobbo G, Fioretti A, Monti V, 
Salerno F. The systemic inflammatory response syndrome in 
cirrhotic patients: relationship with their in-hospital outcome. J 
Hepatol 2009; 51: 475-482 [PMID: 19560225 DOI: 10.1016/
j.jhep.2009.04.017]
59 Bajaj JS, O’Leary JG, Reddy KR, Wong F, Biggins SW, Patton H, 
Fallon MB, Garcia-Tsao G, Maliakkal B, Malik R, Subramanian 
RM, Thacker LR, Kamath PS; North American Consortium For 
The Study Of End-Stage Liver Disease (NACSELD). Survival 
in infection-related acute-on-chronic liver failure is defined by 
extrahepatic organ failures. Hepatology 2014; 60: 250-256 [PMID: 
24677131 DOI: 10.1002/hep.27077]
60 Kim WR, Lake JR, Smith JM, Skeans MA, Schladt DP, Edwards 
EB, Harper AM, Wainright JL, Snyder JJ, Israni AK, Kasiske BL. 
OPTN/SRTR 2015 Annual Data Report: Liver. Am J Transplant 
2017; 17 Suppl 1: 174-251 [PMID: 28052604 DOI: 10.1111/
ajt.14126]
61 Reddy KR, O’Leary JG, Kamath PS, Fallon MB, Biggins SW, 
Wong F, Patton HM, Garcia-Tsao G, Subramanian RM, Thacker 
LR, Bajaj JS; North American Consortium for the Study of End-
Stage Liver Disease. High risk of delisting or death in liver 
transplant candidates following infections: Results from the North 
American Consortium for the Study of End-Stage Liver Disease. 
Liver Transpl 2015; 21: 881-888 [PMID: 25845966 DOI: 10.1002/
lt.24139]
62 Mounzer R, Malik SM, Nasr J, Madani B, Devera ME, Ahmad J. 
Spontaneous bacterial peritonitis before liver transplantation does 
not affect patient survival. Clin Gastroenterol Hepatol 2010; 8: 
623-628.e1 [PMID: 20417723 DOI: 10.1016/j.cgh.2010.04.013]
63 Sun HY, Cacciarelli TV, Singh N. Impact of pretransplant 
infections on clinical outcomes of liver transplant recipients. Liver 
Transpl 2010; 16: 222-228 [PMID: 20104499 DOI: 10.1002/
lt.21982]
64 Lin KH, Liu JW, Chen CL, Wang SH, Lin CC, Liu YW, Yong 
CC, Lin TL, Li WF, Hu TH, Wang CC. Impacts of pretransplant 
infections on clinical outcomes of patients with acute-on-chronic 
liver failure who received living-donor liver transplantation. PLoS 
One 2013; 8: e72893 [PMID: 24023787 DOI: 10.1371/journal.
pone.0072893]
65 Cholongitas E, Germani G, Burroughs AK. Prioritization for liver 
transplantation. Nat Rev Gastroenterol Hepatol 2010; 7: 659-668 
[PMID: 21045793 DOI: 10.1038/nrgastro.2010.169]
66 Cillo U, Burra P, Mazzaferro V, Belli L, Pinna AD, Spada M, 
Nanni Costa A, Toniutto P; I-BELT (Italian Board of Experts in 
the Field of Liver Transplantation). A Multistep, Consensus-Based 
Approach to Organ Allocation in Liver Transplantation: Toward a 
“Blended Principle Model”. Am J Transplant 2015; 15: 2552-2561 
[PMID: 26274338 DOI: 10.1111/ajt.13408]
67 Goldberg DS, Olthoff KM. Standardizing MELD exceptions: 
Current challenges and future directions. Curr Transplant Rep 2014; 
1: 232-237 [PMID: 25530936 DOI: 10.1007/s40472-014-0027-4] 
68 Goldberg D, Bittermann T, Makar G. Lack of standardization in 
exception points for patients with primary sclerosing cholangitis 
and bacterial cholangitis. Am J Transplant 2012; 12: 1603-1609 
[PMID: 22335632 DOI: 10.1111/j.1600-6143.2011.03969.x]
69 Bertuzzo VR, Giannella M, Cucchetti A, Pinna AD, Grossi A, 
Ravaioli M, Del Gaudio M, Cristini F, Viale P, Cescon M. Impact 
of preoperative infection on outcome after liver transplantation. 
Br J Surg 2017; 104: e172-e181 [PMID: 28121031 DOI: 10.1002/
bjs.10449]
70 Artru F, Louvet A, Ruiz I, Levesque E, Labreuche J, Ursic-
Bedoya J, Lassailly G, Dharancy S, Boleslawski E, Lebuffe G, 
Kipnis E, Ichai P, Coilly A, De Martin E, Antonini TM, Vibert E, 
Jaber S, Herrerro A, Samuel D, Duhamel A, Pageaux GP, Mathurin 
P, Saliba F. Liver transplantation in the most severely ill cirrhotic 
patients: A multicenter study in acute-on-chronic liver failure grade 
3. J Hepatol 2017; 67: 708-715 [PMID: 28645736 DOI: 10.1016/
j.jhep.2017.06.009]
71 Giannella M, Bartoletti M, Morelli MC, Tedeschi S, Cristini 
F, Tumietto F, Pasqualini E, Danese I, Campoli C, Lauria ND, 
Faenza S, Ercolani G, Lewis R, Pinna AD, Viale P. Risk factors for 
infection with carbapenem-resistant Klebsiella pneumoniae after 
liver transplantation: the importance of pre- and posttransplant 
colonization. Am J Transplant 2015; 15: 1708-1715 [PMID: 
25754742 DOI: 10.1111/ajt.13136]
72 Giannella M, Trecarichi EM, De Rosa FG, Del Bono V, Bassetti 
M, Lewis RE, Losito AR, Corcione S, Saffioti C, Bartoletti 
M, Maiuro G, Cardellino CS, Tedeschi S, Cauda R, Viscoli C, 
Viale P, Tumbarello M. Risk factors for carbapenem-resistant 
Klebsiella pneumoniae bloodstream infection among rectal 
carriers: a prospective observational multicentre study. Clin 
Microbiol Infect 2014; 20: 1357-1362 [PMID: 24980276 DOI: 
10.1111/1469-0691.12747]
73 Gustot T, Agarwal B. Selected patients with acute-on-chronic 
liver failure grade 3 are not too sick to be considered for liver 
transplantation. J Hepatol 2017; 67: 667-668 [PMID: 28923205 
DOI: 10.1016/j.jhep.2017.07.017]
74 Putignano A, Gustot T. New concepts in acute-on-chronic liver 
failure: Implications for liver transplantation. Liver Transpl 2017; 
23: 234-243 [PMID: 27750389 DOI: 10.1002/lt.24654]
75 de Franchis R; Baveno VI Faculty. Expanding consensus in portal 
hypertension: Report of the Baveno VI Consensus Workshop: 
Stratifying risk and individualizing care for portal hypertension. 
J Hepatol 2015; 63: 743-752 [PMID: 26047908 DOI: 10.1016/
j.jhep.2015.05.022]
76 Tandon P, Delisle A, Topal JE, Garcia-Tsao G. High prevalence 
of antibiotic-resistant bacterial infections among patients with 
cirrhosis at a US liver center. Clin Gastroenterol Hepatol 2012; 10: 
1291-1298 [PMID: 22902776 DOI: 10.1016/j.cgh.2012.08.017]
77 Fernandez J, Tandon P, Mensa J, Garcia-Tsao G. Antibiotic 
prophylaxis in cirrhosis: Good and bad. Hepatology 2016; 63: 
2019-2031 [PMID: 26528864 DOI: 10.1002/hep.28330]
78 Nadim MK, Durand F, Kellum JA, Levitsky J, O’Leary JG, 
Karvellas CJ, Bajaj JS, Davenport A, Jalan R, Angeli P, Caldwell 
SH, Fernández J, Francoz C, Garcia-Tsao G, Ginès P, Ison MG, 
Kramer DJ, Mehta RL, Moreau R, Mulligan D, Olson JC, Pomfret 
EA, Senzolo M, Steadman RH, Subramanian RM, Vincent JL, 
Genyk YS. Management of the critically ill patient with cirrhosis: 
A multidisciplinary perspective. J Hepatol 2016; 64: 717-735 
[PMID: 26519602 DOI: 10.1016/j.jhep.2015.10.019]
79 Tandon P, Abraldes JG, Keough A, Bastiampillai R, Jayakumar 
S, Carbonneau M, Wong E, Kao D, Bain VG, Ma M. Risk 
of Bacterial Infection in Patients With Cirrhosis and Acute 
Variceal Hemorrhage, Based on Child-Pugh Class, and Effects 
of Antibiotics. Clin Gastroenterol Hepatol 2015; 13: 1189-1196.e2 
[PMID: 25460564 DOI: 10.1016/j.cgh.2014.11.019]
80 Weil D, Levesque E, McPhail M, Cavallazzi R, Theocharidou 
E, Cholongitas E, Galbois A, Pan HC, Karvellas CJ, Sauneuf B, 
Robert R, Fichet J, Piton G, Thevenot T, Capellier G, Di Martino 
V; METAREACIR Group. Prognosis of cirrhotic patients admitted 
to intensive care unit: A meta-analysis. Ann Intensive Care 2017; 7: 
33 [PMID: 28321803 DOI: 10.1186/s13613-017-0249-6]
81 Knaak J, McVey M, Bazerbachi F, Goldaracena N, Spetzler V, 
Selzner N, Cattral M, Greig P, Lilly L, McGilvray I, Levy G, 
Ghanekar A, Renner E, Grant D, Hawryluck L, Selzner M. Liver 
transplantation in patients with end-stage liver disease requiring 
intensive care unit admission and intubation. Liver Transpl 2015; 
21: 761-767 [PMID: 25865305 DOI: 10.1002/lt.24115]
82 Grąt M, Hołówko W, Wronka KM, Grąt K, Lewandowski Z, 
Kosińska I, Krasnodębski M, Wasilewicz M, Gałęcka M, Szachta 
P, Zborowska H, Patkowski W, Krawczyk M. The relevance of 
intestinal dysbiosis in liver transplant candidates. Transpl Infect 
Dis 2015; 17: 174-184 [PMID: 25728703 DOI: 10.1111/tid.12352]
83 Safdar N, Said A, Lucey MR. The role of selective digestive 
decontamination for reducing infection in patients undergoing 
liver transplantation: a systematic review and meta-analysis. Liver 
Transpl 2004; 10: 817-827 [PMID: 15237363 DOI: 10.1002/
lt.20108]
84 Rimola A, García-Tsao G, Navasa M, Piddock LJ, Planas R, 
Ferrarese A et al . BI in liver transplantation
230 February 27, 2018|Volume 10|Issue 2|WJH|www.wjgnet.com
Bernard B, Inadomi JM. Diagnosis, treatment and prophylaxis 
of spontaneous bacterial peritonitis: a consensus document. 
International Ascites Club. J Hepatol 2000; 32: 142-153 [PMID: 
10673079]
85 Galbois A, Aegerter P, Martel-Samb P, Housset C, Thabut D, 
Offenstadt G, Ait-Oufella H, Maury E, Guidet B; Collège des 
Utilisateurs des Bases des données en Réanimation (CUB-Réa) 
Group. Improved prognosis of septic shock in patients with 
cirrhosis: a multicenter study. Crit Care Med 2014; 42: 1666-1675 
[PMID: 24732239 DOI: 10.1097/CCM.0000000000000321]
86 Chavez-Tapia NC, Barrientos-Gutierrez T, Tellez-Avila F, 
Soares-Weiser K, Mendez-Sanchez N, Gluud C, Uribe M. Meta-
analysis: antibiotic prophylaxis for cirrhotic patients with upper 
gastrointestinal bleeding - an updated Cochrane review. Aliment 
Pharmacol Ther 2011; 34: 509-518 [PMID: 21707680 DOI: 
10.1111/j.1365-2036.2011.04746.x]
87 European Society of Gastrointestinal Endoscopy, European 
Association for the Study of the Liver. Electronic address: 
easloffice@easloffice.eu; European Association for the Study of 
the Liver. Role of endoscopy in primary sclerosing cholangitis: 
European Society of Gastrointestinal Endoscopy (ESGE) and 
European Association for the Study of the Liver (EASL) Clinical 
Guideline. J Hepatol 2017; 66: 1265-1281 [PMID: 28427764 DOI: 
10.1016/j.jhep.2017.02.013]
P- Reviewer: Kaido T    S- Editor: Cui LJ    L- Editor: A 
E- Editor: Li RF
Ferrarese A et al . BI in liver transplantation
                                      © 2018 Baishideng Publishing Group Inc. All rights reserved.
Published by Baishideng Publishing Group Inc
7901 Stoneridge Drive, Suite 501, Pleasanton, CA 94588, USA
Telephone: +1-925-223-8242
Fax: +1-925-223-8243
E-mail: bpgoffice@wjgnet.com
Help Desk: http://www.f6publishing.com/helpdesk
http://www.wjgnet.com
